|Bid||173.19 x 1100|
|Ask||173.27 x 800|
|Day's Range||170.91 - 173.80|
|52 Week Range||119.38 - 178.44|
|Beta (3Y Monthly)||0.99|
|PE Ratio (TTM)||20.44|
|Earnings Date||Oct 22, 2019 - Oct 28, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||189.18|
LabCorp® (LH) announced today that for the period of Sept. 11, 2019 to March 10, 2020, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the terms of the Zero Coupon Notes, accrue contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading days ended Sept. 6, 2018, in addition to the continued accrual of the original issue discount. Contingent cash interest, which the Company has determined to be approximately $2.81 per Note, will be payable to holders of the Zero Coupon Notes as of the record date, which is Feb. 21, 2020. The payment of contingent cash interest is expected to be made on March 9, 2020.
LabCorp® (LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced that its Covance Drug Development business celebrated the opening of its new R&D Center in Shanghai, China, which is now its largest facility in the Asia Pacific region.
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
LabCorp® (LH) today announced it will participate at the Morgan Stanley Global Healthcare Conference. LabCorp’s presentation is planned for Monday, Sept. 9, 2019 at 9:55 a.m. ET. A live audio webcast will be available via the Company website at www.LabCorp.com and archived for replay.
Boston Microfluidics currently offers two tests for lipids and A1C levels, but CEO Brandon Johnson said the current tool could handle up to 13 tests and potentially more.
Let's talk about the popular Laboratory Corporation of America Holdings (NYSE:LH). The company's shares received a lot...
While rising acquisitions and a favorable mix contribute to LabCorp's (LH) Diagnostics business, the disposition of certain businesses and the implementation of PAMA dented the company's growth in Q2.
LabCorp (LH) delivered earnings and revenue surprises of 1.03% and -0.47%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
Within Covance Drug Development, LabCorp (LH) is focused on driving profitable growth through expanded solutions and enhanced operational capabilities.
LabCorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Another clinical lab ensnared in the AMCA data breach has come forward. Clinical Pathology Laboratories (CPL) says 2.2 million patients may have had their names, addresses, phone numbers, dates of birth, dates of service, balance information and treatment provider information stolen in the previously reported breach. Another 34,500 patients had their credit card or banking information compromised.
CFO, EVP of Laboratory Corp Of America Holdings (LH) Glenn A Eisenberg sold 5,563 shares of LH on 07/08/2019 at an average price of $176.75 a share.
Laboratory Corporation of America Holdings NYSE:LHView full report here! Summary * Perception of the company's creditworthiness is negative * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for LH with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting LH. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $2.64 billion over the last one-month into ETFs that hold LH are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. LH credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.